Skip to main content

Catalyst Calendar

Scope

Thu, Aug 13, 2026

1 updates
PMN
4:00 PM

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes....

Interim Data • Phase 1presentation Tue, Jun 30, 2026promisneurosciences.com

Mon, Aug 3, 2026

1 updates

Tue, Jul 28, 2026

1 updates
PMN
6:00 AM

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, Massachusetts, July 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq:...

Interim Data • Phase 1Results call Tue, Jul 28, 2026, 8:00 AM ETpromisneurosciences.com

Mon, Jul 27, 2026

1 updates
PMN
4:00 PM

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

Cambridge, Massachusetts, July 27, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will host a webinar on Tuesday, July 28, 2026, at 8:00 am ET, featuring Key Opinion...

Results Call • Phase 1Results call Tue, Jul 28, 2026, 8:00 AM ETpromisneurosciences.com

Tue, Jul 14, 2026

1 updates
PMN
2:30 AM

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

PMN310 demonstrated dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid following a single dose in healthy volunteers Represents one of the first quantitative measures of treatment-related effects on oligomer levels in a clinical trial Company on track to present six-month blinded interim data from its Phase 1b trial in the...

Presentation / Abstract • Phase 1AAIC poster presentation Tue, Jul 14, 2026, 7:30 AMpromisneurosciences.com